ompany's research and pre-clinical programs include, Inosine for the
treatment of spinal cord injury and stroke, Oncomodulin for the treatment
of ocular injury and disease and research programs directed at a number of
regenerative therapies including bone repair. The Company has a robust
molecular imaging development program targeting diagnosis of Parkinson's
disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular
imaging candidate, is in Phase III clinical trials for the diagnosis of
Parkinson's disease. Alseres has research collaborations with Harvard
Medical School and Children's Hospital Boston.
Contact: Sharon Correia
Director, Corporate Communications
scorreia@alseres.com
508-497-2360 ext. 224
'/>"/>SOURCE Alseres Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum2.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma3.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference4.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.5.
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study6.
ACG Announces Major Gift by Salix Pharmaceuticals, Inc.7.
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors8.
Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo9.
Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results10.
Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH11.
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia